The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank

A plateau in treatment effect can be seen for the current ‘one-size-fits-all’ approach to oesophageal adenocarcinoma (OAC) management using neoadjuvant chemoradiotherapy (nCRT) or chemotherapy (nCT). In OAC, the tumour microenvironment (TME) is largely immunosuppressed, however a subgroup of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Lonie, James M., Brosda, Sandra, Bonazzi, Vanessa F., Aoude, Lauren G., Patel, Kalpana, Brown, Ian, Sharma, Sowmya, Lampe, Guy, Addala, Venkateswar, Koufariotis, Lambros T., Wood, Scott, Waddell, Nicola, Dolcetti, Riccardo, Barbour, Andrew P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642165/
https://www.ncbi.nlm.nih.gov/pubmed/37965317
http://dx.doi.org/10.3389/fimmu.2023.1220129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642165/
https://www.ncbi.nlm.nih.gov/pubmed/37965317
http://dx.doi.org/10.3389/fimmu.2023.1220129

Ejemplares similares